JPRN-UMIN000002475已完成2 期
Phase II study of combination therapy with S-1 plus cetuximab in patients with EGFR positive KRAS wild type unresectable colorectal cancer, who had previously received on irinotecan, oxaliplatin and fluoropyrimidine(KSCC0901). - Phase II study of 3rd-line therapy with S-1 plus cetuximab in patients with KRAS wild type unresectable colorectal cancer(KSCC0901).
Kyushu Study group of Clinical Cancer0 个研究点目标入组 39 人开始时间: 2009年9月11日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 39
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 80years-old（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1) Severe bone marrow suppression 2) Severe infectious disease 3) Massive pleural effusion or ascites 4) Comorbidity or history of severe heart failure 5) Comorbidity or history of interstitial lung disease or pulmonary fibrosis 6) Paralytic or mechanical bowel obstruction 7) Jaundice 8)History of severe allergy 9)Impossible to evaluate disease by enhanced CT 10)Pregnant or lactating women or women of childbearing potential 11)Severe comorbidity (uncontrolable diabetes, hypertension, hypercarcemia etc) 12)Symptomatic brain metastasis 13)Simultaneous or metachronous double cancers 14)Patients who had received anti EGFR drug that include cetuximab. 15)Any other cases who are regarded as inadequate for study enrollment by the investigator.
研究者
相似试验
已完成
不适用
A phase I/II study of combination therapy with S-1/ CPT-11 plus Panitumumab as second line therapy in metastatic colorectal cancer patients with KRAS wild typeJPRN-UMIN000005218Fukuoka Tumor Research(FUTURE)
招募中
2 期
Feasibility study of combination therapy with S-1 plus irinotecan in patients with EGFR positive KRAS mutation type unresectable colorectal cancer, who had previously received on irinotecan, oxaliplatin and fluoropyrimidine, bevacizumabColorectal cancerJPRN-UMIN0000097343rd department of surgery Tokyo Medical University25
已完成
1 期
Phase I/II study on combination therapy consisting of a fixed dose-rate infusion of gemcitabine with oral fluorinated pyrimidine compound S-1 (FGS) in patients with gemcitabine-refractory advanced pancreatic cancerPatients with gemcitabine-refractory metastatic pancreatic cancerJPRN-C000000450ational Cancer Center Hospital, Hepatobiliary and Pancreatic Oncology Division40
招募中
1 期
Phase 1 clinical study on the combination therapy of CHP-NY-ESO-1 cancer vaccine and Poly-ICLC for the treatment of patients with NY-ESO-1 expressing refractory esophageal cancerRefractory esophageal cancerJPRN-UMIN000007961Kyoto Prefectural University of Medicine18
招募中
2 期
A phase II trial of combination therapy with palonosetron / dexamethasone or palonosetron / aprepitant / dexamethasone for the prevention of chemotherapy-induced nausea and vomiting in patients with urothelial cancer.JPRN-UMIN000010460Yokohama city university80